The Latest Analyst Ratings for Bristol-Myers Squibb
Portfolio Pulse from Benzinga Insights
Bristol-Myers Squibb (NYSE:BMY) has received mixed analyst ratings in the last quarter with 3 bullish, 2 somewhat bullish, 8 indifferent, and 2 somewhat bearish ratings. The average price target is $63.13, representing an upside from the current price of $50.555. This target has decreased by 4.51% from the previous target of $66.11. Analysts rate stocks based on research and provide guidance to investors, though their predictions are opinions and subject to human error.

November 15, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol-Myers Squibb has a mix of analyst ratings with a current average price target of $63.13, which is higher than its current price, indicating potential upside.
The average price target suggests analysts believe the stock has upside potential, which could positively influence investor sentiment and the stock price in the short term. However, the mix of ratings indicates that there is some disagreement among analysts, which could temper the impact. The decrease in the average price target might also cause some concern among investors.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100